Sichuan Kelun-Biotech Biopharmaceutical discovers new TLR7 and TLR8 agonists and immunostimulatory antibody conjugates

April 12, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies covalently linked to TLR7 and/or TLR8 agonists through cleavable or uncleavable linkers.

BioWorld Science Cancer Immuno-oncology Patents

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 11, 2024.

Boryung invests $10M in Intuitive Machines for outer space R&D

BioWorld

Following its $60 million investment in Axiom Space Inc. last year, Boryung Co. Ltd. made a $10 million private placement in Intuitive Machines Inc. to grow its...

Phase II Huntington’s tie-up with Novartis could edge $3B for PTC

BioWorld

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the firm’s Huntington’s disease program with...

Illustration of cancer in the bile ducts

Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal

BioWorld

Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million...

Upgrade your daily dose of biopharma and medtech news

Sichuan Kelun-Biotech Biopharmaceutical discovers new TLR7 and TLR8 agonists and immunostimulatory antibody conjugates